Key result
Acute administration of losartan 50 mg, but not enalapril 10 mg, significantly improved plasma fibrinolytic parameters in heart failure patients, including a 38% reduction in PAI-1 antigen (P<0.001).
Why the study?
Does acute administration of losartan compared to enalapril improve plasma fibrinolytic parameters in patients with moderately severe chronic heart failure?
RCT (n=20)
Single-blind
randomized crossover
Does acute administration of losartan compared to enalapril improve plasma fibrinolytic parameters in patients with moderately severe chronic heart failure?
p-value: p=<0.02
Acute AT1 antagonism with losartan provides a significantly greater improvement in plasma fibrinolytic parameters compared to ACE inhibition with enalapril in patients with heart failure.
Losartan may be preferred acutely over enalapril for fibrinolytic effects in HF; extends evidence distinguishing ARBs from ACEIs on hemostasis.
Angiotensin converting enzyme (ACE) inhibition after myocardial infarction is associated with an improvement in plasma fibrinolytic parameters. The aim of the present study was to determine whether acute ACE inhibition and angiotensin II type 1 (AT1) receptor antagonism have similar effects in patients with heart failure.Twenty patients with moderately severe chronic heart failure received enalapril 10 mg and losartan 50 mg on 2 separate occasions in a single-blind, randomized, crossover design. Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen and activity were measured at baseline and 6 hours after the dose. Acute administration of losartan but not of enalapril reduced plasma t-PA (11%; P=0.003) and PAI-1 (38%; P<0.001) antigen concentrations, which was associated with increases in t-PA (29%; P=0.03) and decreases in PAI-1 (48%; P=0.01) activity. Changes in plasma fibrinolytic parameters were more marked during losartan treatment (P<0.02), with a 3-fold greater reduction in plasma PAI-1 antigen concentrations (P<0.05).Acute AT1 antagonism in patients with heart failure is associated with a significant improvement in plasma fibrinolytic parameters that is greater than during ACE inhibition. These beneficial effects of AT1 antagonism and ACE inhibition would therefore appear to be mediated principally through suppression of angiotensin II.
No takes yet. Share an insight, caveat, or question.
A 2000 study conducted an RCT in moderately severe chronic heart failure (n=20). losartan vs. enalapril 10 mg was evaluated on Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen and activity (p=<0.02). Acute administration of losartan 50 mg, but not enalapril 10 mg, significantly improved plasma fibrinolytic parameters in heart failure patients, including a 38% reduction in PAI-1 antigen (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: